Leslie Storms

Quote

anonymous

Guest
Leslie storms will be the death of Synthes. Many internal changes to become an arthrex model and flood the market with inexperienced reps.

Changing the name of Synthes to J&J Medtech has competitors licking their chops. Late to innovation, and being complacent. Expecting your company to be Ethicon with comp plan changes and being on call 24/7 will drive out the sales force that have been loyal. Let’s invest in unneeded seminars, and recycle ideas from Ethicon!
 






left ortho a couple years ago, havent looked back. I dont talk to my old counterparts as much as I would like to- what exactly is changing? What is the arthrex model?
 






Flooding the market with inexperienced reps. Pushing out leads to have the sales force ran with incompetent people that are case coverage guys making 110k 3 years in. Lack of innovation - Synthes getting out innovated by the likes of Stryker and smith and nephew and launching products that are 6 years late to the market.
 






anonymous said:
Flooding the market with inexperienced reps. Pushing out leads to have the sales force ran with incompetent people that are case coverage guys making 110k 3 years in. Lack of innovation - Synthes getting out innovated by the likes of Stryker and smith and nephew and launching products that are 6 years late to the market.
Click to expand...
if management thinks I will do an ortho TRAUMA job for sub 200k they are out of their minds. These new hires are so dumb they dont even know j&j is screwing them over on pay. but the industry has changed, I bet other companies follow us soon enough.
 






anonymous said:
if management thinks I will do an ortho TRAUMA job for sub 200k they are out of their minds. These new hires are so dumb they dont even know j&j is screwing them over on pay. but the industry has changed, I bet other companies follow us soon enough.
Click to expand...
Completely agree - being on call 24/7. Lots of sacrifice to make 125-150k with a bunch of case coverage guys around. Do better Leslie Storms, you’re going to lose your sales force. This isn’t Ethicon - do a field ride on call the weekend.
 
























It's funny to hear Synthes legacy guys whine about making less than $200k. Face it, the good ole days are gone and not coming back. $200k is fair pay across the industry these days. If you don't like it, go find something better to do with your time. The declining income trend was foreseeable years ago so none of this is new. It's kind of ironic, legacy Synthes guys used to be in it for "the love of the game" helping surgeons do better surgery. Today, it's only about money. Maybe it always was about money but in the old days it felt like there was a greater cause. J&J acquired Synthes over 12 years ago and has fully absorbed the Co. and, for better or worse, merged its culture into J&J's own. Keep in mind, J&J is the best run medical device company in the industry. What's best for the Co. is not always what's best for the individual. As a shareholder, I can't argue with how they've managed Synthes the acquisition.
 






It was always only about the money. Any ortho trauma rep that says otherwise is straight up lying. And yes, I will take my skills elsewhere because this company does pay like shit now. Big guarantees being handed out by the competition.
 






anonymous said:
As a shareholder, I can't argue with how they've managed Synthes the acquisition.
Click to expand...
As a shareholder, I can argue they should have managed not to acquire it for $21B. It was a boondoggle from the very beginning. A DPA right of the bat, plus unbelievable quality remediation; and sucking a ton of budget into direct payments to the AO, which J&J would never ever do, except that AG wanted the deal so the attorneys suddenly found a way to justify it. Sure, Trauma was a major add to the portfolio, but it further wrecked the spine business when they tried to take the whole thing direct and then discovered how much of a disaster that was. We heard all about how the cultures were the same. No they were not. Synthes was hierarchial and DePuy was decentralized (then). Eventually, Synthes was worn down and enough people left and the remainder were assimilated, but it was anything but managed well.
 






anonymous said:
As a shareholder, I can argue they should have managed not to acquire it for $21B. It was a boondoggle from the very beginning. A DPA right of the bat, plus unbelievable quality remediation; and sucking a ton of budget into direct payments to the AO, which J&J would never ever do, except that AG wanted the deal so the attorneys suddenly found a way to justify it. Sure, Trauma was a major add to the portfolio, but it further wrecked the spine business when they tried to take the whole thing direct and then discovered how much of a disaster that was. We heard all about how the cultures were the same. No they were not. Synthes was hierarchial and DePuy was decentralized (then). Eventually, Synthes was worn down and enough people left and the remainder were assimilated, but it was anything but managed well.
Click to expand...
Best Wishes,

Ken
 






KC's survival is somewhat surprising considering his modest academic credentials and limited intellectual assets. He did master the art of playing up to leadership and constantly self-promoting his supposed blue-collar work ethic claiming he outworks everyone (whatever that means). Evidently there are still plenty of places to hide at J&J.
 






anonymous said:
KC's survival is somewhat surprising considering his modest academic credentials and limited intellectual assets. He did master the art of playing up to leadership and constantly self-promoting his supposed blue-collar work ethic claiming he outworks everyone (whatever that means). Evidently there are still plenty of places to hide at J&J.
Click to expand...
It worked for James Brown - "the hardest working man in show business".
 






Top Bottom
Back
Quote